In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
Salk and Indivumed have established a partnership to advance research in precision oncology and personalized medicine
Salk Institute research illustrates how tumors outsmart immune response
Salk researchers get $2.5 million for pancreatic cancer trial involving vitamin D and Keytruda
Collaboration researches first-in-class cancer therapy
miRagen Therapeutics Inc. has released interim results from its ongoing Phase 1 clinical trial of MRG-106 with the mycosis fungoides form of cutaneous T-cell lymphoma
The journal Nature recently published data from STORM Therapeutics that links an essential RNA-modifying enzyme to acute myeloid leukemia (AML).
FDA approves FoundationOne CDx companion diagnostic test for multiple solid tumors
AgeX and BioTime share results on their work with the gene COX7A1, which is linked to tissue regeneration and has potential in the field of cancer
(Photo credit: NCI, NIH)
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

by Dr. Brad Thompson, Oncolytics
During these heady and still-early days in the age of clinical studies involving immunotherapy, it is useful to ponder some of the outstanding questions these studies raise

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.